Dyne Therapeutics shares fall after Novartis Phase 3 setback
Dyne Therapeutics (DYN) shares extended their sell-off on Wednesday, trading 4.2% lower as Wall Street weighed risks to its experimental muscle-disease drug after Novartis’ Phase 3 setback.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.